Cytokine nephropathy during antilymphocyte therapy.
Batiuk
T D
TD
Oregon Health Sciences University, Portland 97201.
Bennett
W M
WM
Norman
D J
DJ
D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology*; D005260:Female; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D007668:Kidney / Q000473:pathology*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D016207:Cytokines; D016853:Muromonab-CD3